Amedeo Smart

Free Medical Literature Service



Breast Cancer

  Free Subscription

Articles published in
Mod Pathol
    May 2021
  1. POLONIA A, Caramelo A
    HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity.
    Mod Pathol. 2021 May 12. pii: 10.1038/s41379-021-00813.
    >> Share

    February 2021
  2. SLEMBROUCK L, Vanden Bempt I, Wildiers H, Smeets A, et al
    Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.
    Mod Pathol. 2021 Feb 8. pii: 10.1038/s41379-021-00743.
    >> Share

  3. TSANG JY, Tse GM
    Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification.
    Mod Pathol. 2021 Feb 2. pii: 10.1038/s41379-021-00736.
    >> Share

  4. KATAYAMA A, Miligy IM, Shiino S, Toss MS, et al
    Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
    Mod Pathol. 2021 Feb 1. pii: 10.1038/s41379-021-00738.
    >> Share

    January 2021
  5. ALHAMAR M, Alkamachi B, Mehrotra H, Sanchez J, et al
    Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents.
    Mod Pathol. 2021 Jan 21. pii: 10.1038/s41379-020-00728.
    >> Share

    November 2020
  6. PASTORELLO RG, Laws A, Grossmith S, King C, et al
    Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer.
    Mod Pathol. 2020 Nov 20. pii: 10.1038/s41379-020-00714.
    >> Share

    October 2020
  7. AI D, Yao J, Yang F, Huo L, et al
    TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
    Mod Pathol. 2020 Oct 3. pii: 10.1038/s41379-020-00692.
    >> Share

    August 2020
  8. ALDREES R, Gao X, Zhang K, Siegal GP, et al
    Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution.
    Mod Pathol. 2020 Aug 10. pii: 10.1038/s41379-020-00650.
    >> Share

  9. BASKOTA SU, Dabbs DJ, Clark BZ, Bhargava R, et al
    Prosigna(R) breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK) index for breast cancer prognosis.
    Mod Pathol. 2020 Aug 1. pii: 10.1038/s41379-020-0643.
    >> Share

    July 2020
  10. BHARGAVA R, Esposito NN, O'Connor SM, Li Z, et al
    Magee Equations and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
    Mod Pathol. 2020 Jul 13. pii: 10.1038/s41379-020-0620.
    >> Share

  11. KUBA MG, Lester SC, Bowman T, Stokes SM, et al
    Histopathologic features of breast cancer in Li-Fraumeni syndrome.
    Mod Pathol. 2020 Jul 7. pii: 10.1038/s41379-020-0610.
    >> Share

  12. CHEN R, Qarmali M, Siegal GP, Wei S, et al
    Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
    Mod Pathol. 2020 Jul 3. pii: 10.1038/s41379-020-0615.
    >> Share

    June 2020
  13. CHRISTGEN M, Bartels S, van Luttikhuizen JL, Bublitz J, et al
    E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements.
    Mod Pathol. 2020 Jun 22. pii: 10.1038/s41379-020-0591.
    >> Share

    May 2020
  14. ALSALEEM MA, Ball G, Toss MS, Raafat S, et al
    A novel prognostic two-gene signature for triple negative breast cancer.
    Mod Pathol. 2020 May 13. pii: 10.1038/s41379-020-0563.
    >> Share

  15. FARSHID G, Dhatrak D, Gilhotra A, Koszyca B, et al
    The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
    Mod Pathol. 2020 May 4. pii: 10.1038/s41379-020-0555.
    >> Share

    April 2020
  16. ZHU MMT, Burugu S, Gao D, Yu J, et al
    Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
    Mod Pathol. 2020 Apr 29. pii: 10.1038/s41379-020-0550.
    >> Share

  17. REISENBICHLER ES, Han G, Bellizzi A, Bossuyt V, et al
    Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
    Mod Pathol. 2020 Apr 16. pii: 10.1038/s41379-020-0544.
    >> Share

    March 2020
  18. BHARGAVA R, Clark BZ, Carter GJ, Brufsky AM, et al
    The healthcare value of the Magee Decision Algorithm: use of Magee Equations and mitosis score to safely forgo molecular testing in breast cancer.
    Mod Pathol. 2020 Mar 17. pii: 10.1038/s41379-020-0521.
    >> Share

  19. WANG X, Teng X, Ding W, Sun K, et al
    A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of >/=2.0 but an average HER2 copy number of <4.0 signals per cell.
    Mod Pathol. 2020 Mar 16. pii: 10.1038/s41379-020-0519.
    >> Share

  20. DANO H, Altinay S, Arnould L, Bletard N, et al
    Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.
    Mod Pathol. 2020;33:354-366.
    >> Share

    February 2020
  21. AGAHOZO MC, van Bockstal MR, Groenendijk FH, van den Bosch TPP, et al
    Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
    Mod Pathol. 2020;33:196-205.
    >> Share

    August 2019
  22. LANJEWAR S, Patil P, Fineberg S
    Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States.
    Mod Pathol. 2019 Aug 5. pii: 10.1038/s41379-019-0326.
    >> Share

  23. LYAPICHEV KA, Pina-Oviedo S, Medeiros LJ, Evans MG, et al
    A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma.
    Mod Pathol. 2019 Aug 5. pii: 10.1038/s41379-019-0337.
    >> Share

    June 2019
  24. LOBO J, Petronilho S, Newell AH, Coach J, et al
    E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients.
    Mod Pathol. 2019 Jun 23. pii: 10.1038/s41379-019-0294.
    >> Share

    April 2019
  25. ABUBAKAR M, Figueroa J, Ali HR, Blows F, et al
    Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
    Mod Pathol. 2019 Apr 11. pii: 10.1038/s41379-019-0270.
    >> Share

    October 2018
  26. CLARK BZ, Onisko A, Assylbekova B, Li X, et al
    Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity.
    Mod Pathol. 2018 Oct 16. pii: 10.1038/s41379-018-0153.
    >> Share

    August 2018
  27. ROSS DS, Zehir A, Brogi E, Konno F, et al
    Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
    Mod Pathol. 2018 Aug 29. pii: 10.1038/s41379-018-0116.
    >> Share

  28. LEE M, Heo SH, Song IH, Rajayi H, et al
    Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis.
    Mod Pathol. 2018 Aug 28. pii: 10.1038/s41379-018-0113.
    >> Share

  29. RIMM DL, Leung SCY, McShane LM, Bai Y, et al
    An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer.
    Mod Pathol. 2018 Aug 24. pii: 10.1038/s41379-018-0109.
    >> Share

    June 2018
  30. SONBUL SN, Aleskandarany MA, Kurozumi S, Joseph C, et al
    Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.
    Mod Pathol. 2018 Jun 28. pii: 10.1038/s41379-018-0092.
    >> Share

    May 2018
  31. DILL EA, Dillon PM, Bullock TN, Mills AM, et al
    IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
    Mod Pathol. 2018 May 25. pii: 10.1038/s41379-018-0061.
    >> Share

    April 2018
    Expanding definitions of HER2 positivity.
    Mod Pathol. 2018;31:685.
    >> Share

  33. STEWART RL, Gulbahce EH, Geiersbach KB, Downs-Kelly E, et al
    Reply to Commentary on 'HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features'.
    Mod Pathol. 2018;31:686.
    >> Share

    October 2017
  34. ADAMS TA, Vail PJ, Ruiz A, Mollaee M, et al
    Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer.
    Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.
    >> Share

  35. SANCHEZ-MUNOZ A, Vicioso L, Santonja A, Alvarez M, et al
    Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016